Inito Gets US patent for Diagnostics Technology
Inito is a Bangalore based medical technology startup. Initio is now India’s first Y-Combinator backed MedTech startup that has been granted patent rights for their Flat-lens technology by the US Patent and Trademark Office. US patent will further Inito’s mission of becoming a global health-tech company out of India.
The patented Flat-lens technology allows the Inito devices to perform dozens of lab-grade diagnostic tests at home just by using a smartphone and also a low-cost device. Inito device comes with the Inito Reader, App, and also the Test strips. A sample is put on the test strip and the strip is inserted into the Inito device. The Initio device is then attached to the phone whose camera captures images of the strip through the flat lens. The Initio device also automatically calibrates the variations between different phones and gives the same accuracy irrespective of the phones used. The Inito app will display the result of the test and also tracks the values for analysis.
Fertility is the first
test that is supported by the Inito device. The device enables women to track their fertile days at home itself and increase their chances of getting pregnant by 89 percent. The device does so by measuring 2 fertility hormones, Estrogen & Luteinizing Hormone (LH) in the urine. Inito’s AI-based app then uses data to understand cycle variations for every user and gives highly accurate results that are unique to every woman’s body. The test results have been found to be 99.12% correlated with those obtained from lab-grade scanners in a study conducted by the Indian Institute of Technology, Delhi.The data set of hormones that is collected through 150,000 plus tests taken on the Initio device is arguably the largest cloud-based dataset of fertility hormones in the world. And in the next one year, Inito has some plans to add 8 more hormone tests to the device. Coupled with big data analytics and artificial intelligence, the device will be able to predict several key metrics of fertility for its users and diagnose various fertility conditions like anovulatory cycles, PCOS, etc. without going to the lab. By doing this, the Initio company aims to disrupt the US$30 billion fertility market.
Commenting on this news, Mr. Aayush Rai, Co-Founder, and CEO, Inito said that Inito’s Flat Lens technology is the world’s leading smartphone-connected technology that allows one to perform dozens of tests on our phone. The patent grant by the US Patent Office provides Initio defensibility in the global market and will help them cement their leadership position in bringing the quality diagnostic tests to every home, he added.
Author: Ria Roy
